Our portfolio

Ellogon.ai

Ellogon’s AI-driven cancer diagnostics solution quantifies oncology biomarkers in complex histopathological slides with limited annotations. Traditional supervised deep learning requires exhaustive annotation by pathologists, which is impractical due to the enormous size and complexity of histopathology slides. Ellogon however, uses sparse-shot learning to achieve high accuracy with significantly fewer annotations, making it a game-changer in the field of digital pathology.

Industry: AI, Diagnostics, Digital Health, Oncology

Want to get in contact about Ellogon.ai?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Ross Gordon

Chemistry, Biotech & AI

Our portfolio

Check out similar ventures

Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.

OpticsFoundry

Simplifying quantum technology, we robotically manufacture glued optical circuit boards, enabling easier design and production of complex optical systems.
Advancing molecular diagnostics for precision oncology and infectious diseases.
Improving orthopedic diagnostics with advanced joint loading and imaging technology.
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.

OpticsFoundry

Simplifying quantum technology, we robotically manufacture glued optical circuit boards, enabling easier design and production of complex optical systems.
Advancing molecular diagnostics for precision oncology and infectious diseases.
Improving orthopedic diagnostics with advanced joint loading and imaging technology.